The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars

Panelists discuss how stakeholders can enhance biosimilar uptake through coordinated efforts in financial alignment, patient-centric pricing, professional education, simplified administrative processes, and collaborative data exchange.

EP: 1.Clinical Value of Biosimilars and the Role of Interchangeability

EP: 2.The Economic Impact of Biosimilars

EP: 3.Best Practices for Employers to Maximize Uptake of Biosimilars

EP: 4.The Role of Private Label Agreements in Enhancing Access to Biosimilars

EP: 5.Key Structural and Operational Considerations for Biosimilar Adoption

EP: 6.Positioning Biosimilars in Clinical Practice

EP: 7.Assessing Patient Confidence With Biosimilars

Now Viewing

EP: 8.The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars

Video content above is prompted by the following:

• How can different stakeholders such as providers, health systems, insurance providers, and pharmacy benefit managers work together more efficiently to optimize the uptake of biosimilars?

Related Videos

Related Content

Advertisement

February 28th 2025

AHA, ACC Update Guidelines for Acute Coronary Syndrome Management

Giuliana Grossi

The 2025 guideline introduces notable updates including refined recommendations for dual antiplatelet therapy, cardiogenic shock management, and secondary prevention.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

February 28th 2025

Falls, Balance Issues Signal Higher ICANS Risk in NHL

Tim Cortese

Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

February 26th 2025

Disease Burden From Myasthenia Gravis Consistently High

Maggie L. Shaw

Myasthenia gravis is becoming increasingly common around the world, with a resulting disease burden beset by high health care resource utilization, decreased quality of life, and worsened mental health.

Published: February 25th 2025 | Updated: February 25th 2025

Dry Eye Symptom Frequency, Severity Reduced When Using Perfluorohexyloctane

Julia Bonavitacola

Perfluorohexyloctane ophthalmic solution had high treatment satisfaction in those who took it for dry eye.

Related Content

Advertisement

February 28th 2025

AHA, ACC Update Guidelines for Acute Coronary Syndrome Management

Giuliana Grossi

The 2025 guideline introduces notable updates including refined recommendations for dual antiplatelet therapy, cardiogenic shock management, and secondary prevention.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

February 28th 2025

Falls, Balance Issues Signal Higher ICANS Risk in NHL

Tim Cortese

Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

February 26th 2025

Disease Burden From Myasthenia Gravis Consistently High

Maggie L. Shaw

Myasthenia gravis is becoming increasingly common around the world, with a resulting disease burden beset by high health care resource utilization, decreased quality of life, and worsened mental health.

Published: February 25th 2025 | Updated: February 25th 2025

Dry Eye Symptom Frequency, Severity Reduced When Using Perfluorohexyloctane

Julia Bonavitacola

Perfluorohexyloctane ophthalmic solution had high treatment satisfaction in those who took it for dry eye.